The Latest

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive // IPO window

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    Scribe’s IPO haul is the smallest among the 14 biotechs to go public this year. But the company is one of only two to price an offering without a drug that’s already in Phase 2 testing or later, data show.

    Updated July 24, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma

    Novo is seeking an injunction that would halt allegedly “misleading” obesity drug ads. Elsewhere, the FDA began reviewing a highly anticipated medicine and a veteran investor landed at an AI startup.

  • A modern architectural design building featuring a red-brick façade with large glass windows displays a prominent sign of the Food and Drug Administration.
    Image attribution tooltip
    Alamy
    Image attribution tooltip
    Trump administration

    5 FDA decisions to watch in the third quarter of 2026

    A group of coming decisions could provide important insights into how flexible the agency is willing to be under new leadership.

    FDA
  • A photo of a building showing a GSK sign in London.
    Image attribution tooltip
    Courtesy of GSK
    Image attribution tooltip

    GSK lung cancer drug gets speedy approval following $10.6B deal

    The clearance is GSK’s first for a lung cancer medicine and the latest step forward in a yearslong push by the British drugmaker into oncology.

  • An injection pen containing the drug semaglutide lies on a white plate.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Obesity drugs

    Novo sues Lilly, alleging ‘misleading’ advertising of obesity drugs

    The lawsuit follows a cease-and-desist request and argues Lilly is using “deceptive” ads to claim its GLP-1 products are broadly superior to Novo’s medicines. Lilly countered that its campaign is “truthful.”

  • An illustration of Red and white blood cells inside a vein or artery.
    Image attribution tooltip
    SpiffyJ via Getty Images
    Image attribution tooltip

    Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug

    To analysts, the drug’s apparent safety and effects on both triglyceride levels and pancreatitis cases should make it competitive with a rival Ionis therapy.

  • President Donald Trump holds up his hands in the Oval Office of the White House on June 11, 2026 in Washington, DC.
    Image attribution tooltip
    Alex Wong via Getty Images
    Image attribution tooltip
    Trump administration

    Trump threatens tariffs on imported generic drugs

    While the possibility of levies on branded pharmaceuticals have had a limited impact on drugmaker revenues, tariffs of up to 200% on copycat medicines could — depending on the specifics — prove more disruptive.

  • A photo of the three founders of Dimension
    Image attribution tooltip
    Permission granted by Dimension
    Image attribution tooltip
    Emerging biotech

    Dimension restocks with $800M to capitalize on AI’s ‘rapid ascent’

    The young venture firm, which has bet heavily on tech and biotech’s convergence, has now invested in 35 companies and recently saw one of them acquired by AI giant Anthropic.

  • A person cradles their foot at the metatarsophalangeal joints.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    Crystalys nets $130M more to push gout drug through late-stage tests

    The startup has a broad global development program underway — and the support of more than 20 investment firms — for a treatment that’s approved in many Asian countries but isn’t yet available in the U.S. or Europe.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study

    A new analysis could address some doubts investors have had about ivonescimab, one analyst said. Elsewhere, Gilead and Merck debuted data for a once-weekly HIV tablet and a new pyschedelics competitor emerged.

  • A sign spelling Novartis hangs on the side of a building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Novartis climbs on upbeat drug sales as key readouts loom

    A return to quarterly sales growth boosted shares higher on Tuesday, though a handful of coming study results will have a bigger impact on the company’s long-term outlook.

  • An illustration of sickled red blood cells.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Agios scraps sickle cell drug

    The study failure costs Agios a chance to one-up Novo Nordisk and represents yet another setback in a disease that’s frustrated drugmakers of late.

  • Front view of the NASDAQ MarketSite, which occupies the northwest corner at the base of the 4 Times Square building, in Midtown Manhattan, New York City.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    IPO window

    Pain drugmaker Latigo outlines plans to go public

    The Westlake-founded company specializes in non-opioid drugs that target sodium ion channels, and is now adding to what’s already been a busy month for the biotech IPO queue.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Bristol Myers to build ‘powerful’ AI factory; Samsung Biologics bids for peptide maker

    Bristol Myers is the third pharmaceutical company to recently seek Nvidia’s help building a large AI data center. Elsewhere, a Novartis kidney drug gained a leg up on competitors.

  • A person holds a GLP-1 injection drug with the cap off.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Obesity drugs

    Compounders maintain a firm grip on the GLP-1 market

    Despite an FDA crackdown, numerous pharma lawsuits and possible safety risks, nearly 1 in 5 patients are still taking cheaper weight-loss alternatives.

  • A person wearing a blue glove holds a test tube with red liquid
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Tempus to acquire cancer test maker Personalis for $1.5B

    Tempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.

  • A sign with the letters GSK hangs on the side of an office building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    GSK shelves cough drug acquired in $2B deal

    Mixed Phase 3 data for camlipixant prompted the British pharma to cease development, making the drug the third from its class to fail.

  • psychedelic pill
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Lilly to buy AtaiBeckley for $2.8B, further validating psychedelics

    The latest in a prolific streak of buyouts by Lilly is the strongest sign yet that large pharmaceutical companies may finally be embracing a long-dismissed field of research.

  • A wall showing a Merck & Co. logo in Kenilworth, New Jersey
    Image attribution tooltip
    Courtesy of Merck & Co.
    Image attribution tooltip

    Merck wins first approval of a PCSK9 cholesterol pill

    The speedy clearance of Lipfendra is an important milestone for Merck and the result of a controversial voucher program put in place by former FDA commissioner Marty Makary.  

    Updated July 16, 2026
  • A clear drop with a dollar symbol is pipetted into a test tube.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    Biotech startup funding gap widens despite rebound in VC investment

    Though funding totals represented the highest first-half sum since the start of 2022, industry watchers are concerned that small startups are being left behind.

  • An unrecognizable woman has problems with hair and scalp
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Veradermics keeps ‘momentum going’ as baldness drug helps women with hair loss

    The Phase 2 data exceeded expectations, lifting company shares as high as nearly $130 apiece and building the case for what may be the first pill specifically approved for female pattern hair loss.

  • robot hand
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    How well are AI-discovered drugs faring in the clinic?

    Some of the industry’s most closely-watched AI drugs could provide insight into the success of technology-assisted development.

  • Pills lie on top of hundred dollar bills.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Jasper gets a lifeline in merger with immune drugmaker Kira

    The acquisition, which involves a concurrent licensing deal with startup Mirador, gives Jasper a chance to rebound from setbacks that have wiped out most of its market value.  

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Arbutus, Sanofi escalate mRNA patent fights; InnoCare’s TYK2 contender advances

    The new lawsuits add to a web of legal disputes over technology involved in COVID vaccines. Elsewhere, a prolific AI biotech inked another deal and Insmed strengthened support for a closely watched blood pressure drug.

  • A sign spelling Merck hangs on the side of an office building
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Merck ADC, in China study, shows potential to replace chemo in lung cancer

    The results were seen by Wall Street analysts as “direct proof-of-concept” that sac-TMT, a drug Merck views as a “cornerstone,” could be part of a future treatment standard for front-line lung cancer.